Dr. Niran J. Amar, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Years since graduation
- 56
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 272
Licensed in Texas since 1982, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
TX license G2305 (first issued 1982; active) -
Clinical & Laboratory Immunology (Allergy & Immunology) Physician
TX license G2305 (first issued 1982; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Allergy and Asthma Center PA (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 272
- Services billed
- 9,280
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 4,133 | 65 |
| Professional service for preparation and provision of 1 or more antigens | 2,206 | 170 |
| Professional service for single injection of allergen | 1,843 | 112 |
| Professional service for multiple injections of allergen | 1,267 | 68 |
| Established patient office or other outpatient visit, 30-39 minutes | 208 | 126 |
| Established patient office or other outpatient visit, 20-29 minutes | 203 | 154 |
| Test to measure expiratory airflow and volume | 138 | 84 |
| Test for allergy using allergenic extract injected into skin | 46 | 13 |
| Administration of influenza virus vaccine | 42 | 42 |
| Influenza vaccine split virus, preservative free | 41 | 41 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluticasone Propionate Other prescribers in Waco, TX | 344 |
| Azelastine Hcl Other prescribers in Waco, TX | 212 |
| Montelukast Sodium Other prescribers in Waco, TX | 171 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Waco, TX | 159 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Waco, TX | 154 |
| Epinephrine Other prescribers in Waco, TX | 93 |
| Levocetirizine Dihydrochloride Other prescribers in Waco, TX | 72 |
| Ventolin Hfa (albuterol sulfate) Other prescribers in Waco, TX | 58 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Waco, TX | 54 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Waco, TX | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 30 payments worth $769 in total to this clinician.
| Genzyme Corporation | $118 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $98.34 |
| Csl Behring | $83.71 |
| Radius Health, Inc. | $82.03 |
| Blueprint Medicines Corporation | $47.70 |
| GlaxoSmithKline, LLC. | $43.76 |
| Novartis Pharmaceuticals Corporation | $35.98 |
| Cequr Corporation | $35.98 |
| Food and Beverage | $636 |
|---|---|
| Education | $132 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Apr 29, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $98.34 |
| Amgen Inc. Aug 12, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $16,248 in research payments for these studies, mostly to the institutions running them.
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
AstraZeneca Pharmaceuticals LP - A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Eli Lilly and Company · Active, not recruiting · NCT06339008 - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.